Status:
COMPLETED
Anti-Cytokine Therapy for Vasculitis
Lead Sponsor:
University Hospital Birmingham NHS Foundation Trust
Conditions:
Wegener's Granulomatosis
Renal Limited Vasculitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Infliximab (monoclonal anti-tumour necrosis factor alpha antibodies) are safe and effective in the treatment of anti-neutrophil cytoplasm antibody (AN...
Detailed Description
Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis is a life-threatening systemic inflammatory autoimmune disease. Current treatment regimes using corticosteroids and cyclophosphamide hav...
Eligibility Criteria
Inclusion
- Either newly diagnosed or relapsed ANCA associated vasculitis (Wegener's granulomatosis, microscopic polyangiitis, renal limited vasculitis)
Exclusion
- Active infection
- Malignancy
- Pregnancy
- Diagnosis of Churg-Strauss syndrome or anti-glomerular basement membrane antibody disease
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00753103
Start Date
January 1 2003
End Date
July 1 2006
Last Update
September 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom, B15 2TT